Interview with Alessandro Busca, Director of SSD Stem Cell Transplant Center, AOU Città della Salute e della Scienza of Turin
Genomic analysis has now become a fundamental aspect for our clinical practice, because many haematological neoplasms – I mention above all acute myeloid leukemia, myelodysplesias, myelofibrosis and myeloma itself – require a very accurate analysis and diagnosis on the basis of these genomic tests, because subsequent therapies can be aimed at targeting certain tumor markers, thus avoiding chemotherapy treatments which are still fundamental but which, as we know, affect all cells”.
Talking during the two days of work “ONCOnnection States General NORTH WEST – LIGURIA, LOMBARDY, PIEDMONT, VALLE D’AOSTA”promoted by Healthcare Engine with the unconditional contribution of Johnson & Johnson Med Tech, Sobi rare strength, Merck, GSK, And Alessandro BuscaDirector SSD Stem Cell Transplant Center, AOU Città della Salute e della Scienza of Turin.
“Nowadays – continues Busca – medicine is moving towards a target therapy that targets a specific tumor marker”.
YOU MAY ALSO BE INTERESTED IN: Pneumonia alarm in children: 2 cases of mycoplasma in Italy – experts urge caution, A new therapy for Fanconi Bickel syndrome, Covid and flu, few vaccinations, cases are growing. Risks for the fragile